Podcasts about perelman school

The No Surprises Act was designed to protect patients from unexpected medical bills, but nearly four years after the law took effect, many experts say parts of its implementation aren't working as intended. Insurers, hospitals, physician groups and federal regulators continue to battle over the law's payment dispute process, raising questions about whether one of the nation's most significant health care consumer protection laws is achieving its goals.In this special live episode of Tradeoffs, host Dan Gorenstein moderates a conversation with three leading experts on surprise medical billing, health insurance regulation and federal health policy. They explain how the No Surprises Act was implemented, how litigation has shaped the arbitration process, why providers have won a disproportionate share of payment disputes and what policymakers could do to improve the law.Guests:Zack Cooper, Associate Professor of Public Health and of Economics, Yale University; Director of Health Policy, Tobin Center for Economic Policy; Director, Health Care Affordability Lab at YaleBenjamin Chartock, Assistant Professor of Economics, Bentley UniversityLindsey Murtagh, Senior Fellow in Health Services, Policy and Practice, Brown University School of Public HealthRachel Werner, Executive Director, Leonard Davis Institute of Health Economics; Professor of Medicine, Perelman School of Medicine, University of PennsylvaniaLearn more: Read the full reporting and explore additional resources on our website.Want more Tradeoffs? Join more than 5,500 readers who trust Tradeoffs for clear, deeply reported health policy insights. Sign up for our free weekly newsletter.Tradeoffs helps you cut through the noise with clear, deeply reported journalism on the forces driving health care's toughest choices — reporting you won't find anywhere else. If our work helps you stay informed, support it with a donation today. Hosted on Acast. See acast.com/privacy for more information.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours NZ listeners - save 10% off Calocurb by using the code Mikkipedia10 at www.calocurb.co.nzThis week on the podcast, Mikki speaks to Dr Matt Bernstein, a physician working in the emerging field of metabolic psychiatry, which explores the connection between brain health, metabolism, and mental illness.In this episode, the conversation centres on how metabolic dysfunction may play a far greater role in mental health than traditionally recognised. Matt explains what metabolic psychiatry actually is, how it differs from conventional psychiatric approaches, and why factors like insulin resistance, inflammation, and mitochondrial dysfunction are now being considered key drivers in conditions such as depression, anxiety, and more severe psychiatric disorders.They explore the growing interest in nutritional and metabolic interventions, including dietary strategies like carbohydrate restriction, and how these may influence brain energy, neurotransmitter function, and symptom outcomes. The discussion also touches on where the evidence currently sits, what clinicians should be cautious about, and how to think about integrating these approaches alongside standard care.It's a thought-provoking conversation that challenges traditional models of mental health, while offering a more biologically grounded way of understanding and supporting the brain.Dr. Matt Bernstein is a highly respected clinical psychiatrist and a leading voice in metabolic psychiatry, with 25 years of experience helping individuals achieve full mental health and functional recovery.He graduated summa cum laude from Columbia University in English literature and earned his medical degree from the Perelman School of Medicine at the University of Pennsylvania. Trained at MGH/McLean, he served as chief resident and later held leadership roles including psychiatrist-in-charge and assistant medical director of the schizophrenia and bipolar inpatient program. He also serves as chief medical officer at Ellenhorn, developing community-based strategies to optimize mental health.For the past five years, Dr. Bernstein has focused on metabolic psychiatry, first in his private practice, and then at Ellenhorn. More recently, he created Accord's comprehensive program and is sharing his expertise through podcasts, national conferences, and briefings for members of Congress. He co-organized the first public conference on metabolic psychiatry, and co-leads a privately funded study evaluating outcomes of Accord's pioneering interventions.He serves on advisory and non-profit boards, including Metabolic Mind, Meru Health, The Metabolic Revolution, and the Coalition for Metabolic Health, helping advance the field both clinically and publicly.https://accordmh.com/our-team/matt-bernstein/ Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

Drag by 2 PM? In this Supplement Ingredient Series episode, Nurse Doza breaks down NAD+, the coenzyme your cells use to make energy (ATP), and why levels dip with age and stress. He explains how NAD+ injections at home through SHED's provider-guided telehealth program offer a convenient way to support steady all-day energy, sharper focus, and less brain fog. Try it with code DOZA40 for 40% off. Featured Partner: SHED SHED is a telehealth provider that ships physician-reviewed NAD+ at-home injection kits, so you can keep a consistent NAD+ routine without booking a clinic IV drip — exactly the kind of convenient, repeatable protocol Nurse Doza describes in this episode. Always follow the dosing and technique guidance from your SHED provider.

In this episode, we are joined by Dr. Matt Bernstein, MD, Chief Medical Officer at Ellenhorn and Chief Executive Officer of Accord. A highly respected clinical psychiatrist and leading voice in the emerging field of metabolic psychiatry, Dr. Bernstein draws on more than 25 years of experience helping individuals achieve meaningful mental health improvement and long-term functional recovery. Throughout his career, Dr. Bernstein has explored the connection between metabolism and mental health, first through private practice and later through his work at Ellenhorn. More recently, he developed Accord's comprehensive treatment model and has become a prominent advocate for metabolic psychiatry through podcasts, national conferences, and briefings for members of Congress.   This conversation dives into: What metabolic psychiatry is and how it differs from traditional psychiatric care. The relationship between brain metabolism and mental health disorders. How ketogenic therapies are being explored as potential tools for psychiatric recovery. The role of metabolic health in conditions such as depression, bipolar disorder, schizophrenia, anxiety, OCD, and psychosis. Dr. Bernstein graduated summa cum laude from Columbia University with a degree in English Literature and earned his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his psychiatric training at MGH/McLean, where he served as Chief Resident and later held leadership positions, including Psychiatrist-in-Charge and Assistant Medical Director of the Schizophrenia and Bipolar Inpatient Program. He also serves on several advisory and nonprofit boards, including Metabolic Mind, Meru Health, The Metabolic Revolution, and the Coalition for Metabolic Health. Connect with Dr. Bernstein: LinkedIn Accord's Website Ellenhorn's Website

In this Huberman Lab Essentials episode, my guest is Dr. Casey Halpern, MD, a professor of neurosurgery at the Perelman School of Medicine at the University of Pennsylvania. We discuss how deep brain stimulation and other neuromodulation approaches are being used to treat Parkinson's disease, obsessive-compulsive disorder (OCD), binge eating disorder and depression-related symptoms. We also explore the brain circuits that drive compulsions, cravings and impulsivity, as well as emerging non-invasive tools for predicting and treating harmful behaviors. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Function: https://functionhealth.com/huberman Rorra: https://rorra.com.huberman Timestamps (00:00:00) Casey Halpern (00:00:20) Neurosurgery, Deep Brain Stimulation (00:04:19) Obsessive-Compulsive Disorder (OCD) & Treatments (00:10:11) Sponsor: Function (00:11:49) OCD Brain Areas, Addiction (00:14:12) Nucleus Accumbens, Risk & Rewards; Binge Eating Disorder (00:18:28) Sponsor: AG1 (00:19:46) Non-Invasive Brain Stimulation, Transcranial Magnetic Stimulation (00:27:31) Sponsor: Rorra (00:28:46) Awareness of Cravings, Severe Binge Eating Disorder (00:32:51) Artificial Intelligence/Machine Learning & Predicting Impulsive Behavior (00:36:57) Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

8:05PM: El Niño has been making headlines lately as this year, we're in for a “Super” El Niño. What exactly does that mean, and how will it affect Massachusetts and beyond? Guest: Dr. Emily Becker, Research Associate Professor in the Department of Atmospheric Sciences at the University of Miami's Rosenstiel School of Marine and Atmospheric Studies 8:15PM: Local kids facing serious illness & disability take the field with college athletes at Boston College for Team IMPACT’s 4th annual Boston College Field Day this Sunday, May 3, from 2-4 PM. Guest: Maura Ambrose, Regional Executive Director, Northeast at Team IMPACT 8:30PM: It’s college graduation time, and today’s graduates will be setting off to pursue careers they’ve spent years preparing for. They believe they have it all figured out, but this year’s college graduates are expected to change careers at least 5 times. Why is this? Guest: Marcy Fitzgerald, author of the critically acclaimed new book, “Finding Your Space: A Permission Slip for High Achievers to Evolve, Pivot, and Thrive on Their Own Terms” 8:45PM: Nuclear medicine may just be the answer for many cancer patients. Nuclear medicine uses radioactive material, and doctors say it can be a lifesaver. With radiation exposure known for causing cancer and damaging DNA, how could it possibly heal? Guest: Dr. Phil Mulugeta, Clinical Director, Division of Nuclear Medicine Imaging and Therapy at Penn Medicine and Associate Professor of Clinical Radiology at Perelman School of Medicine, UPennSee omnystudio.com/listener for privacy information.

Guest: Abdallah Geara, MD IgA nephropathy is often asymptomatic and frequently identified through incidental lab findings, making timely recognition challenging. Hear Dr. Abdallah Geara discuss key diagnostic strategies that may help optimize long-term care for this disease. Dr. Geara is an Associate Professor of Clinical Medicine and the Clinical Director of the Glomerular Disease Program at the Perelman School of Medicine at the University of Pennsylvania, and he spoke at the 2026 National Kidney Foundation Spring Clinical Meeting.

Matters Microbial #128: C. diff from Nursery to Nursing Home April 20, 2026 Today Dr. Joseph Zackular, Assistant Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, joins the #QualityQuorum to discuss some fascinating microbiology involving the bacterium Clostridiodes difficile (also known as C. diff), which can cause disease in infants, the elderly, and the immunocompromised. Host: Mark O. Martin Guest: Joseph Zackular Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An essay about siderophores in bacteria. The Giant Microbes "Cdiff" toy. The website of Dr. Patrick Schloss. A link to the #MattersMicrobial podcast with Dr. Schloss. An overview of Clostridioides difficile from a patient / physician perspective. A review article of research involving Clostridioides difficile. An overview on polymicrobial diseases. A wonderful opinion piece by Dr. Arturo Casadevall regarding the term "pathogen." An overview of Enterococcus in the gut microbiome. The technology of imaging mass spectrometry. An article on Stickland fermentation of amino acids among gut bacteria. Work by Dr. Zackular and colleagues discussed in this podcast, describing how FMT can be used as a treatment. Work by Dr. Zackular and colleagues discussed in this podcast, describing how different members of the host microbiome interact, and how that relates to disease. Work by Dr. Zackular and colleagues discussed in this podcast, describing the role of amino acid metabolism to changes in microbiome structure. Work by Dr. Zackular and colleagues discussed in this podcast, describing how Enterococcus can modulate the disease causing characteristics of C. difficile. An interesting paper showing that polymicrobial effects are more common than expected. An article arguing that there is no single "healthy" microbiome. A lovely primer on this topic for most nonmicrobiologists.  An overview on fecal microbiome transplants and the treatment of human disease. The website for the Center for Microbial Medicine at the University of Pennsylvania. A great video by Dr. Zackular and colleagues, well worth your time. Dr. Zackular's academic website. Dr. Zackular's laboratory website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Jordan W. Swanson, MD, discuss the following articles from the April 2026 issue: "A Comparison of Surgical Techniques for Macroglossia in Beckwith-Wiedemann Syndrome" by Romeo, Lenz, George, et al. Read the article for FREE: https://bit.ly/BeckwithSyndrome  Special guest Dr. Jordan Swanson is the Linton Whitaker Endowed Chair of Craniofacial Surgery at the Children's Hospital of Philadelphia and an associate professor of surgery at the Perelman School of Medicine at the University of Pennsylvania. He specializes in the care of patients with cleft lip and palate, craniosynostosis, and other craniofacial conditions, as well as adult craniofacial and aesthetic surgery. His work in global partnerships with teams in low- and middle-income countries has spanned more than a decade, including collaboration with the Nicaraguan Ministry of Health, where he helped build a joint, comprehensive cleft and craniofacial program. He has also led initiatives to expand access to high-quality surgical care in low-resource settings through his clinical practice, research, and global health leadership. Dr. Swanson advances surgical innovation, education, and care delivery across diverse healthcare contexts. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCApril26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Jordan W. Swanson, MD, discuss the following articles from the April 2026 issue: "Primary Septal Cartilage Graft for Unilateral Cleft Rhinoplasty: 10-Year Follow-Up Results and the Effect on Septal Deviation" by Ueno, Fukui, Yao, et al. Read the article for FREE: https://bit.ly/UniCleft10Yr Special guest Dr. Jordan Swanson is the Linton Whitaker Endowed Chair of Craniofacial Surgery at the Children's Hospital of Philadelphia and an associate professor of surgery at the Perelman School of Medicine at the University of Pennsylvania. He specializes in the care of patients with cleft lip and palate, craniosynostosis, and other craniofacial conditions, as well as adult craniofacial and aesthetic surgery. His work in global partnerships with teams in low- and middle-income countries has spanned more than a decade, including collaboration with the Nicaraguan Ministry of Health, where he helped build a joint, comprehensive cleft and craniofacial program. He has also led initiatives to expand access to high-quality surgical care in low-resource settings through his clinical practice, research, and global health leadership. Dr. Swanson advances surgical innovation, education, and care delivery across diverse healthcare contexts. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCApril26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Jordan W. Swanson, MD, discuss the following articles from the April 2026 issue: "Influence of Surgical Technique and Surgical Skill on Outcomes of Cleft Palate Repair" by Sitzman, Kirschner, Temkit, et al. Read the article for FREE: https://bit.ly/CleftPalateFistula Special guest Dr. Jordan Swanson is the Linton Whitaker Endowed Chair of Craniofacial Surgery at the Children's Hospital of Philadelphia and an associate professor of surgery at the Perelman School of Medicine at the University of Pennsylvania. He specializes in the care of patients with cleft lip and palate, craniosynostosis, and other craniofacial conditions, as well as adult craniofacial and aesthetic surgery. His work in global partnerships with teams in low- and middle-income countries has spanned more than a decade, including collaboration with the Nicaraguan Ministry of Health, where he helped build a joint, comprehensive cleft and craniofacial program. He has also led initiatives to expand access to high-quality surgical care in low-resource settings through his clinical practice, research, and global health leadership. Dr. Swanson advances surgical innovation, education, and care delivery across diverse healthcare contexts. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCApril26Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In addition to being a respected clinical psychiatrist for more than 20 years, Dr. Matt Bernstein is Accord's chief executive officer and one of the leading voices in the emerging field of metabolic psychiatry. After graduating summa cum laude from Columbia University in New York, N.Y., with a bachelor's degree in English literature, he received his medical degree from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. Dr. Bernstein then trained at the MGH McLean Psychiatry Residency Program in Belmont, Mass., where he served as chief resident. He remained at McLean Hospital after residency as a psychiatrist-in-charge and later served as assistant medical director of its schizophrenia and bipolar inpatient program. Dr. Bernstein has developed his passion for community-based care as the chief medical officer at Ellenhorn, a sister program of Accord, where he has pursued alternative ways (such as a focus on metabolism, nutrition, circadian-rhythm biology and exercise) to help individuals achieve their best levels of functioning without relying solely on traditional psychiatric approaches. In addition to serving on the clinical advisory board at Metabolic Mind, Dr. Bernstein is known for organizing the first-ever public conference on metabolic psychiatry in 2023. SHOWNOTES:

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Jordan W. Swanson, MD, discuss the following articles from the April 2026 issue:  "Influence of Surgical Technique and Surgical Skill on Outcomes of Cleft Palate Repair" by Sitzman, Kirschner, Temkit, et al. "Primary Septal Cartilage Graft for Unilateral Cleft Rhinoplasty: 10-Year Follow-Up Results and the Effect on Septal Deviation" by Ueno, Fukui, Yao, et al. "A Comparison of Surgical Techniques for Macroglossia in Beckwith-Wiedemann Syndrome" by Romeo, Lenz, George, et al. Special guest Dr. Jordan Swanson is the Linton Whitaker Endowed Chair of Craniofacial Surgery at the Children's Hospital of Philadelphia and an associate professor of surgery at the Perelman School of Medicine at the University of Pennsylvania. He specializes in the care of patients with cleft lip and palate, craniosynostosis, and other craniofacial conditions, as well as adult craniofacial and aesthetic surgery.  His work in global partnerships with teams in low- and middle-income countries has spanned more than a decade, including collaboration with the Nicaraguan Ministry of Health, where he helped build a joint, comprehensive cleft and craniofacial program. He has also led initiatives to expand access to high-quality surgical care in low-resource settings through his clinical practice, research, and global health leadership. Dr. Swanson advances surgical innovation, education, and care delivery across diverse healthcare contexts. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCApril26Collection  The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In SRNA's Ask the Expert episode moderated by Krissy Dilger, Dr. Elena Grebenciucova described neuromyelitis optica spectrum disorder (NMOSD) symptoms including optic neuritis, transverse myelitis, brainstem syndromes, and intractable hiccups [00:01:05]. She outlined diagnostic evaluation using MRI and correct blood-based antibody testing (preferably cell-based assays), common diagnostic pitfalls, and the need to rule out infections before immunosuppressive treatment [07:08]. Dr. Grebenciucova reviewed urgent relapse management with IV steroids and early plasma exchange, side effects, long-term preventive therapies (FDA-approved and off-label) [14:02]. Finally, she answered community questions on supplements, chronic optic neuritis, rehab appeals, pain/spasticity, pregnancy planning, long-term treatment duration, mental health, seronegative syndromes, follow-up frequency, and recovery expectations [25:22].Elena Grebenciucova, MD completed neurology residency at the University of Chicago in Chicago, Illinois. Dr. Grebenciucova has been interested in autoimmune disorders of the central nervous system, including rare neuroimmune disorders, since medical school. After residency, she completed a neuroimmunology Fellowship under the mentorship of Dr. Brenda Banwell and Joseph Berger at the Perelman School of Medicine of The University of Pennsylvania. Currently she is an assistant professor of Neurology (MS/Neuroimmunology) and neurological infections at Northwestern University in Chicago, Illinois, and she runs the Transverse Myelitis Center there. Dr Grebenciucova sees patients with rare autoimmune conditions including NMOSD, MOGAD, transverse myelitis, and autoimmune encephalitis.00:00 Welcome and Introduction01:05 What Is NMOSD?01:59 Symptoms and Relapse Signs03:27 What Causes NMOSD?07:08 How NMOSD Is Diagnosed10:09 Key Tests and Pitfalls14:02 Acute Attack Treatment17:18 Steroid Side Effects22:19 Long-Term Therapies Worldwide25:22 Community Questions, Beginning with Vitamins27:40 Optic Neuritis Breakthroughs28:47 Chronic Optic Nerve Inflammation29:19 Winning Insurance Appeals31:23 Waist Band Pain and Spasticity34:04 Pregnancy and Family Planning37:40 Stopping Long-Term Treatment39:40 Long-Term Side Effects43:04 Mood and Personality Changes49:47 Trials for Seronegative NMOSD52:55 Follow Up Visit Schedule55:34 Relapse Recovery Timeline58:02 Closing

In early January 2026, the U.S. Centers for Disease Control and Prevention announced changes to the childhood immunization schedules, reducing the number of vaccines recommended for children. This change led to the U.S. being an outlier in terms of required vaccines for children. One reason people express concern about vaccines is fear of adverse reactions. It may surprise many that there is a comprehensive system in place to monitor adverse outcomes, and this is the topic of this episode with guest Dr. Jeffrey Morris. Dr. Jeffrey Morris is the George S. Pepper Professor of Public Health and Preventative Medicine and Director Biostatistics Division, Department of Biostatistics, Epidemiology and Informatics at the Perelman School of Medicine University of Pennsylvania. He has been actively involved in scientific communication efforts on social media and with various media outlets. He is also a distinguished research fellow at the Annenberg Center for Public Policy.

With the rapid increase in the use of BTK inhibitors managing CV risk is increasingly challenging and important. In this episode leading experts from the University of Pennsylvania medical school guide us through some of these complexities. Watch to the full webinar here: https://www.radcliffecardiology.com/webinars/managing-cv-risk-patients-cll Dr. Emily Tomasulo is a Hematologist/Oncologist who specializes in B-cell lymphoma and cellular therapy at Pennsylvania Hospital and the Hospital of the University of Pennsylvania. She sits on ECOG-ACRIN Leukemia Committee and her research and clinical interests focus on the use of targeted and cellular therapies in B-cell malignancies with particular attention to cardiovascular adverse effects.Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and Medical Director of the Thalheimer Center for Cardio-Oncology. He trained at Yale University, Johns Hopkins University, and Massachusetts General Hospital. His clinical and research interests focus on arrhythmic complications of cancer therapies. He currently serves as President of the International Cardio-Oncology Society (IC-OS).

Three hundred and thirty-two days, that was the international statistic of the year in 2020, as identified by the Royal Statistical Society. That was the length of time between scientists publishing the genetic sequence of COVID-19 on the 11th of January, and an effective vaccine being administered on the 8th of December. This vaccine was an integral part of the world's pandemic response. Vaccines aren't new. In a World Health Organization report describing the history of vaccines, Dr. Edward Jenner is credited with the world's first successful vaccine for smallpox in 1796. In the last 100 years, vaccines were developed for yellow fever, pertussis, polio, hepatitis B, measles, mumps, rubella, and more. Well, how do we know vaccines are safe and effective? Why do some people argue against using vaccines? That's the topic of this episode with guest Dr. Jeffery Morris. Dr. Jeffrey Morris is the George S. Pepper Professor of Public Health and Preventative Medicine and Director Biostatistics Division, Department of Biostatistics, Epidemiology and Informatics at the Perelman School of Medicine University of Pennsylvania. He has been actively involved in scientific communication efforts on social media and with various media outlets. He is also a distinguished research fellow at the Annenberg Center for Public Policy.

Host Dr. Larry Barsh sits down with two frontline Philadelphia healthcare providers to discuss the mounting health crisis driven by fear of immigration enforcement in immigrant communities. The conversation draws on a powerful New York Times op-ed the guests co-authored in February, titled "Our Patients Are More Frightened and Sicker Than Ever," and explores real patient stories, systemic failures, and what listeners can do to help.Dr. Robin Canada - Professor of Clinical Medicine, University of Pennsylvania's Perelman School of Medicine. Primary care physician and community health leader serving as Associate Division Chief for Community Engagement and Director of Residency Education at a clinic specifically for immigrant patients in South Philadelphia. Co-author of the February New York Times op-ed.Elizabeth Whidden - Fifth-year MD/MPH student at the University of Pennsylvania, months away from beginning her residency in internal medicine. Former immigrant case manager. Current leader of an organization coordinating medical-legal partnerships for asylum seekers. Co-author of the February New York Times op-ed.Widespread fear in immigrant communities is causing patients to avoid medical care, even those with legal status.ICE activity has been described as indiscriminate — affecting documented residents, mixed-status families, and U.S. citizens.Medical Consequences of DetentionInterruption of medications for diabetes, hypertension, post-stroke care, dialysis, and addiction leads to rapid deterioration.Reportedly 40+ detainee deaths in 2025; 6–8 already reported in 2026 (exact figures uncertain).An ACLU analysis found roughly 95% of detention deaths between 2021–2024 were preventable with proper medical care.Detained individuals face lack of food access, irregular bathroom schedules, absence of exercise, and extreme psychological stress.How Clinics Are Responding Switching to phone-based telemedicine appointments when ICE threat levels are high.Locking clinic waiting rooms to prevent unannounced ICE entry; installing security in the vestibule.Increased proactive outreach to high-risk patients who have stopped coming in.Writing letters of medical necessity for detained patients to support legal and consulate efforts.Coordinating medical-legal partnerships for asylum seekers through student-led organizations.Relevance to SeniorsMany caregivers in senior living and skilled nursing facilities come from immigrant communities — ICE enforcement directly disrupts elder care.Undocumented seniors are also directly affected — the episode highlights a man in his late 60s on dialysis being worked up for cancer who lives under dual threats of illness and deportation.How You Can HelpDonate to legal aid organizations in your city — immigration lawyers are working around the clock on habeas petitions and there is a serious shortage.Support safety-net clinics caring for immigrant patients — these communities often have no access to Medicaid, Medicare, or food assistance.Search for immigrant rights organizations in your city — most have a "how to help" section on their website with both financial and volunteer opportunities.Attend protests and rallies — as Dr. Canada notes, the world is watching, and advocacy from seniors carries special weight.Stay informed and speak out — sharing the realities of what is happening in your community can shift the conversation.Referenced Article"Our Patients Are More Frightened and Sicker Than Ever" — New York Times op-ed, February 2025, by Dr. Robin Canada and Elizabeth Whidden. The piece describes the devastating health consequences of immigration enforcement on patients in Philadelphia's South Side and calls for systemic reform.Article by Dr, Canadahttps://closler.org/passion-in-the-medical-profession/detained

Today, Kevin Lee, an undergrad at the University of Pennsylvania, talks with Dr. Theodore Drivas MD, PhD, assistant professor in Translational Medicine and Human Genetics at the Perelman School of Medicine. In this episode, Dr. Drivas talks about his path to clinical and research work, his passion in disease of the primary cilium, and current challenges in genetic analysis of rare and common disease. 

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Scott P. Bartlett, MD, discuss the following articles from the February 2026 issue: "Anthropometrics versus Experts' Subjective Analysis of Cleft Severity and PSIO Outcomes in Unilateral Clefts: A Proposal for a New Grading" by Tanikawa, Chong, Fisher, et al. "A Modified Method for Ear Projection in Auricular Reconstruction: Split-Thickness Skin Graft Combined with Retroauricular Fascia Flap for Postauricular Coverage" by Li, Feng, Hu, et al. "Total Ear Reconstruction with Costal Cartilage  in Challenging Cases: Silicone-Induced Vascularized Capsule Technique" by Park.  Special guest Dr. Scott P. Bartlett. Dr. Bartlett is one of the world's leading craniofacial surgeons and serves as Director of the Craniofacial Program and an attending surgeon in the Division of Plastic, Reconstructive, and Oral Surgery at the Children's Hospital of Philadelphia. He is also a Professor of Surgery at the Perelman School of Medicine at the University of Pennsylvania and holds the prestigious Mary Downs Endowed Chair in Pediatric Craniofacial Treatment and Research at CHOP. Dr. Bartlett's clinical expertise encompasses congenital and acquired deformities of the skull, face, jaws, and ears, as well as complex facial aesthetic and reconstructive surgery. He served two terms as Section Editor for the Pediatric Craniofacial Section of Plastic and Reconstructive Surgery. His research portfolio includes landmark contributions to facial growth and development, age-related facial structural changes, non-surgical correction of ear deformities, and the use of advanced imaging and implant materials to improve operative planning and long-term outcomes. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCFeb26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode, Suchi Patel sits down with Zarina S. Ali, MD, Chief of Neurosurgery at Penn Presbyterian Medical Center and Associate Professor of Neurosurgery at the Perelman School of Medicine. Dr. Ali shares insights from her pioneering career in neurosurgery, discussing the clinical complexities in high-grade brain tumors, and her research into optimizing patient outcomes through data-driven approaches like ERAS and GREEN OR. The conversation explores the intersection of academic medicine and healthcare innovation with Dr. Ali's inspiration of going into neurosurgery. Edited by Suchi Patel and Divyash Shah

In this episode of PRIM&R's podcast, "Research Ethics Reimagined," we explore FDA's plausible mechanism pathway for ultra-rare genetic disorders with Holly Fernandez Lynch, Associate Professor of Medical Ethics at the University of Pennsylvania's Perelman School of Medicine. She discusses how this pathway enables personalized gene therapies for N-of-one or N-of-few diseases while raising important questions about regulatory process, evidence standards, and equitable access. Professor Fernandez Lynch also examines the remarkable case of baby KJ, who received a gene editor to treat his urea cycle disorder, and considers both the transformative potential and the procedural concerns surrounding FDA's approach. 

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Scott P. Bartlett, MD, discuss the following articles from the February 2026 issue: "Total Ear Reconstruction with Costal Cartilage in Challenging Cases: Silicone-Induced Vascularized Capsule Technique" by Park. Read the article for FREE: https://bit.ly/TotalEarRecon Special guest Dr. Scott P. Bartlett. Dr. Bartlett is one of the world's leading craniofacial surgeons and serves as Director of the Craniofacial Program and an attending surgeon in the Division of Plastic, Reconstructive, and Oral Surgery at the Children's Hospital of Philadelphia. He is also a Professor of Surgery at the Perelman School of Medicine at the University of Pennsylvania and holds the prestigious Mary Downs Endowed Chair in Pediatric Craniofacial Treatment and Research at CHOP. Dr. Bartlett's clinical expertise encompasses congenital and acquired deformities of the skull, face, jaws, and ears, as well as complex facial aesthetic and reconstructive surgery. He served two terms as Section Editor for the Pediatric Craniofacial Section of Plastic and Reconstructive Surgery. His research portfolio includes landmark contributions to facial growth and development, age-related facial structural changes, non-surgical correction of ear deformities, and the use of advanced imaging and implant materials to improve operative planning and long-term outcomes. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCFeb26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Scott P. Bartlett, MD, discuss the following articles from the February 2026 issue: "A Modified Method for Ear Projection in Auricular Reconstruction: Split-Thickness Skin Graft Combined with Retroauricular Fascia Flap for Postauricular Coverage" by Li, Feng, Hu, et al. Read the article for FREE: https://bit.ly/EarElevationRecon Special guest Dr. Scott P. Bartlett. Dr. Bartlett is one of the world's leading craniofacial surgeons and serves as Director of the Craniofacial Program and an attending surgeon in the Division of Plastic, Reconstructive, and Oral Surgery at the Children's Hospital of Philadelphia. He is also a Professor of Surgery at the Perelman School of Medicine at the University of Pennsylvania and holds the prestigious Mary Downs Endowed Chair in Pediatric Craniofacial Treatment and Research at CHOP. Dr. Bartlett's clinical expertise encompasses congenital and acquired deformities of the skull, face, jaws, and ears, as well as complex facial aesthetic and reconstructive surgery. He served two terms as Section Editor for the Pediatric Craniofacial Section of Plastic and Reconstructive Surgery. His research portfolio includes landmark contributions to facial growth and development, age-related facial structural changes, non-surgical correction of ear deformities, and the use of advanced imaging and implant materials to improve operative planning and long-term outcomes. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCFeb26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Contributor: Alec Coston, MD Educational Pearls: Disclaimer: this has nothing to do with the ER but is too cool to not talk about. Condition: Carbamoyl phosphate synthetase 1 (CPS1) deficiency Rare inborn error of metabolism Inability to properly break down ammonia Leads to severe hyperammonemia and hepatic encephalopathy Natural history: Without treatment, typically fatal within the first few weeks of life Even with current standard treatments, life expectancy is often limited to ~5–6 years Breakthrough treatment: A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the CRISPR-based targeted gene therapy for this patient. First-of-its-kind precision approach tailored to the patient's specific mutation Key components of the therapy: Whole-genome sequencing to identify the exact CPS1 mutation Creation of a custom base-editing enzyme designed to correct that specific mutation Design of a guide RNA to direct the base editor to the precise genomic location Delivery method: Lipid nanoparticles used to deliver the gene-editing machinery Nanoparticles can be targeted to specific tissues Why the liver works well: CPS1 is primarily expressed in hepatocytes The liver is relatively easy to target with lipid nanoparticles Hepatocytes divide frequently, allowing edited genes to be passed on as cells replicate Long-term impact: Once edited, cells continue producing functional CPS1 enzyme Potential for durable, possibly lifelong correction from a single treatment References https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022 Feb 1;526:55-61. doi: 10.1016/j.cca.2021.11.029. Epub 2021 Dec 29. PMID: 34973183. Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026 Jan 5. doi: 10.1039/d5na00535c. Epub ahead of print. PMID: 41640466; PMCID: PMC12865601. Summarized and edited by Jeffrey Olson MS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf

Desmond Patton is the 31st PIK University Professor at the University of Pennsylvania, with joint appointments in the School of Social Policy & Practice and the Annenberg School for Communication, where he is the Waldo E Johnson Jr. Professor of Communication. He also holds secondary appointments in the Department of Psychiatry at Children's Hospital of Philadelphia & Perelman School of Medicine. He is founding director of SAFElab, founding faculty director of the Penn Center for Inclusive Innovation & Technology, and Chief Strategy Officer for the School of Social Policy & Practice.Professor Patton's groundbreaking research examines the relationship between social media and gun violence, grief, and loss, focusing on how online communities influence offline behavior. His work has made him the most cited and widely recognized scholar in this critical area of social science. Early research focused on detecting trauma and preventing violence on social media has evolved into broader investigations of language analysis and algorithmic bias in artificial intelligence. He currently serves as a member of Spotify's Safety Advisory Council, the Ethics and Equity Advisory Council (EEAC) at Axon, TikTok's U.S. Content Advisory Council, and is a trusted advisor to several AI startups.As a social work scientist, Patton identified that traditional data science methods often fail to capture the cultural and linguistic nuances of predominantly Black and Hispanic youth. In response, he developed the Contextual Analysis of Social Media (CASM) framework, which integrates culture, context, and inclusion into machine learning and computer vision analysis. He is also pioneering a new research agenda on joy, developing a practical and theoretical framework for integrating joy into AI model development as a tool for equity, imagination, and human connection.Dr. Patton is a member of the National Academy of Medicine, an Obama Foundation USA Leader, a Mozilla Rise 25 Change Agent, a Presidential Leadership Scholar, and one of RockHealth's Top 50 in Digital Health.Links:https://sp2.upenn.edu/person/desmond-upton-patton/https://bsky.app/profile/did:plc:dxheqqkccc6z5kqgw34shta7https://www.linkedin.com/in/desmond-patton-49a7b59/ Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Scott P. Bartlett, MD, discuss the following articles from the February 2026 issue: "Anthropometrics versus Experts' Subjective Analysis of Cleft Severity and PSIO Outcomes in Unilateral Clefts: A Proposal for a New Grading" by Tanikawa, Chong, Fisher, et al. Read the article for FREE: https://bit.ly/PSIOoutcomes Special guest Dr. Scott P. Bartlett. Dr. Bartlett is one of the world's leading craniofacial surgeons and serves as Director of the Craniofacial Program and an attending surgeon in the Division of Plastic, Reconstructive, and Oral Surgery at the Children's Hospital of Philadelphia. He is also a Professor of Surgery at the Perelman School of Medicine at the University of Pennsylvania and holds the prestigious Mary Downs Endowed Chair in Pediatric Craniofacial Treatment and Research at CHOP. Dr. Bartlett's clinical expertise encompasses congenital and acquired deformities of the skull, face, jaws, and ears, as well as complex facial aesthetic and reconstructive surgery. He served two terms as Section Editor for the Pediatric Craniofacial Section of Plastic and Reconstructive Surgery. His research portfolio includes landmark contributions to facial growth and development, age-related facial structural changes, non-surgical correction of ear deformities, and the use of advanced imaging and implant materials to improve operative planning and long-term outcomes. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCFeb26Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

When it comes to “bad” cholesterol, most cardiologists say lower is better. But what's the best way to get that number down? Can diet and exercise alone do the job?Cardiologists Kiran Musunuru and Neha Pagidipati join Host Ira Flatow for a look at the latest in cholesterol-lowering treatments, including CRISPR technology that could turn off cholesterol-making genes for life. How does it work, and is it safe?Guests:Dr. Kiran Musunuru is the scientific director of the Center for Inherited Cardiovascular Disease at the Perelman School of Medicine at the University of Pennsylvania.Dr. Neha Pagidipati is the director of the Cardiometabolic Prevention Clinic at the Duke University School of Medicine in Durham, NC.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

If you go by pop culture depictions, menopause seems like no big deal — a few hot flashes, some comical bouts of hormone-fueled rage, and the “big change,” as it was once called, is over. But for many of the 2 million American women who enter menopause each year, the symptoms can be a lot more serious and long-lasting, ranging from vertigo and joint pain to brain fog and heart problems.On this episode, we take a deep dive into perimenopause and menopause – what's going on biologically? What can be done to ease symptoms? And why do so many women struggle to receive help from their doctors?We talk with menopause experts about hormone replacement therapy, and why it was demonized for many years; find out what researchers have discovered about the causes of brain fog; and hear about new efforts to deal with medically induced menopause. In this excerpt from our live event, Reimagining Menopause, host Maiken Scott talks with two certified menopause providers — Robyn Faye, an OB-GYN at Jefferson Health in Philadelphia, and Arina Chesnokova, assistant professor in of Obstetrics and Gynecology at the University of Pennsylvania's Perelman School of Medicine — about the ins and outs of hormone therapy, which symptoms it alleviates, when it's safe and when it's not. Watch the full discussion here. Reporter Alan Yu talks with researchers about what's behind one of the most vexing symptoms of menopause for many women — brain fog. For women who have cancer when they're younger, especially breast or ovarian cancer, chemotherapy and other medications needed to treat the disease can affect hormones - and suddenly plunge them into menopause, years before they might naturally experience it. We explore what their options are, and why so many say they were not prepared for this change.

Rural health experts dig into the Trump administration's effort to transform rural health care.Guests:Kevin Bennett, Director Center for Rural & Primary Healthcare; Professor, Family and Preventative Medicine, School of Medicine Columbia, University of South CarolinaPaula Chatterjee, Director of Health Equity Research, Penn LDI; Assistant Professor, Medicine, Perelman School of MedicineSarah Jane Tribble, Chief Rural Correspondent, KFF Health NewsRachel Werner, Executive Director, Leonard Davis Institute of Health Economics; Professor of Medicine, Perelman School of Medicine, University of PennsylvaniaLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Dr. Alison Loren and Dr. Ann Partridge share the latest guideline from ASCO on the management of cancer during pregnancy. They highlight the importance of this multidisciplinary, evidence-based guideline and overarching principles for the management of cancer during pregnancy. Drs. Loren and Partridge discuss key recommendations from each section of the guideline, including diagnostic evaluation, oncologic management, obstetrical management, and psychological and social support. They also touch on the importance of this guideline and accompanying tools for clinicians and how this serves as a framework for pregnant patients with cancer. The conversation wraps up with a discussion on the unanswered questions and how future evidence will inform guideline updates.  Read the full guideline, "Management of Cancer During Pregnancy: ASCO Guideline" at www.asco.org/survivorship-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/survivorship-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02115   Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Alison Loren from the Perelman School of Medicine of the University of Pennsylvania and Dr. Ann Partridge from Dana-Farber Cancer Institute, co-chairs on "Management of Cancer During Pregnancy: ASCO Guideline." Thank you for being here today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks for having us. Dr. Ann Partridge: It's a pleasure. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Partridge and Dr. Loren who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into the meat of this guideline, to start us off, Dr. Loren, could you provide an overview of the scope and purpose of this new guideline on the optimal management of cancer during pregnancy? Dr. Alison Loren: Sure, thanks, Brittany. So this was really born out of I think a lot of passion and concern for this really vulnerable patient population. We have observed, and I am sure it is not any surprise to your audience, that the incidence of cancer in young people is increasing. And simultaneously, people are choosing to become pregnant at older ages, and so we are seeing more and more people with a cancer diagnosis during their pregnancy. And for probably obvious reasons, there is really no way to do randomized clinical trials in this population. And so really trying to assemble and articulate the best evidence for safely managing the diagnosis of cancer, the management of cancer once it is confirmed, being thoughtful about obviously the health of the mom, but also attending to potential risks to the developing fetus, and really just trying to be really comprehensive and balanced about all the choices for these patients when they are facing some really challenging decisions in a very emotionally fraught environment. And I think it is really emotionally fraught for the providers, too. You know, this is obviously an extremely intense, very emotional set of decisions, and so trying to provide a rudder essentially to sort of help people frame the questions and trying to make as evidence-based a set of recommendations as possible. Dr. Ann Partridge: And I would just add that "evidence-based" is a strong word here because typically our, as you just heard, our gold standard evidence is a randomized trial, but you can't do that in this setting, in general. And so, what we were able to do with the support of the phenomenal ASCO staff was to pull together kind of the world's literature on the safety and outcomes of treatments during pregnancy, as well as consensus opinion. And I think that is a really, really critical difference about this particular guideline compared to many of the other ones that ASCO does, where consensus and good judgment needed to kind of rule the day when evidence is not available. So, there is a lot of that in our recommendations. Dr. Alison Loren: That is such a good point. And I just, before we move forward, I just want to reflect that the composition of the panel was really broad and wide-ranging. We had maternal medicine specialists, we had legal and ethical experts, we had representatives who understand pharmaceutical industries' perspectives, and then medical oncologists representing the full spectrum of oncology diagnoses. And so it was a really diverse, in terms of expertise, panel, internationally composed to try to really get the best consensus that we could in the absence of gold standard evidence. Brittany Harvey: Absolutely. That multidisciplinary panel is really key to developing this guideline and, as you said, looking at the evidence and even though it does not reach the level of randomized trials, still critically evaluating it and reviewing that along with consensus to come up with optimal management for diagnosis and management of cancer during pregnancy. So then to follow that up, I would like to next review the key recommendations of the guideline across the main sections that the expert panel provided. First, I will throw this out to either of you, but what are the important general principles for the management of cancer during pregnancy? Dr. Ann Partridge: I think there were three major principles that we hammer home in the guidelines. One is that this is a team sport. It is multidisciplinary care that is necessary in order to optimize outcomes for the patient and potentially for the fetus. And that you really need to, from the beginning, bring in a coordinated team, including not just oncologists but obstetricians, maternal-fetal medicine specialists, neonatologists, ethics consultants, and obviously the patient and potentially her family. So that, I think, is one of the most important things. Second would be that obviously in a pregnancy, there are two potential patients and that the nuances of safety and risk from treatment is really wrapped up in where in the trimester of the pregnancy the patient is diagnosed, along with the kind of cancer that it is, both the urgency of treatment and the risk of the cancer, as well as the potential risks of any given intervention across the cancer continuum. It is a broad guideline in that regard. And then finally, and this is particularly timely given what is going on from a sociopolitical standpoint in the U.S., really thinking about informed consent and potential ethical as well as legal implications of some of the choices that patients might have when they are thinking about, in particular, continuing a pregnancy or potential termination. Dr. Alison Loren: And I will just add that I think that the key to all of this guidance is nuance and individualization and also making sure that patients and their care providers understand all the choices that are available to them and also the consequences of those choices. You know, nobody would choose to receive chemotherapy during pregnancy if that wasn't necessary. So there are risks to treatment, but there are also risks to not treatment. And making sure that in a suboptimal situation where you do not have a lot of evidence, trying to weigh, the best you can, the risks and benefits of all of the choices so that the patient can come to a decision about the treatment plan that is right for her. Brittany Harvey: Definitely. And those core concepts really set the stage for individualized care on what is necessary for appropriate multidisciplinary care, prioritizing both patient autonomy and informed decision making. With those core concepts and key principles in mind, I would like to move into the recommendations section of the guideline. So what are the key recommendations regarding diagnostic evaluation for pregnant patients with signs or symptoms of cancer? Dr. Alison Loren: I think the most important thing is to not delay, that there are very careful and well-thought-out recommendations for how to evaluate a potential cancer. And while there are certain things that we know can be harmful, particularly when certain dose thresholds are exceeded - for instance, abdominal imaging, there are certain radiographic thresholds that you don't want to exceed because of risk of harm to the embryo or fetus - there are still lots of options for diagnosing cancer during pregnancy. And again, thinking about the costs of not doing versus the cost of doing, right? It is really important to make the diagnosis of cancer if that is a consideration or a concern. And sometimes going directly to biopsies or getting definitive studies, even if there is a small risk to the developing fetus, is really essential because if the mom does not survive, of course, the fetus is also not going to survive. And so we need to be thinking first about the patient who is sitting in front of us, the woman who needs to know what is going on in her body so she can make good decisions about her health. So, I think that is a key principle in thinking about this. Brittany Harvey: Absolutely. So, following that diagnosis of a new or recurrent cancer, what is recommended for oncologic management of patients who are diagnosed with cancer during their pregnancy? Dr. Ann Partridge: So, I think the general principle is, again, cancer is such a wide number of diseases and even within diseases, a range of stages and risks and associated opportunities for risk reduction and/or treatment depending on the type of cancer. Just by example, in the work that I do, which is breast cancer, once someone has had a surgery in the early-stage setting, a lot of our treatment is about risk reduction. And that is very different than from what Alison does, which is treating people with leukemia, where it is kind of binary. If you do not treat, including with cytotoxic drugs, the patient and an unborn fetus will die, especially early in the pregnancy, obviously. So this is where cancers are very, very different. So I think taking the approach of what would you do if the patient were not pregnant? And what is the best treatment for that particular patient with that particular kind of cancer? And then applying the pregnancy and where the patient is in that pregnancy in terms of the trimester of the pregnancy, and what is safe and what is unsafe from the options that you would give her if she were not pregnant. And then if the patient is choosing to keep the pregnancy, which in my practice, many people come and they come to me because they want to hold onto their pregnancy and want to figure out how to make it work, coming up with a regimen that tries to give them kind of the best bang for the buck, the best possible breast cancer therapy with the least harm, when possible, to the fetus. It is a bit of a balance, right? And then we cannot always give people the best approach. And sometimes it comes down to making a decision to give up something that may improve their survival so as not to harm the fetus. And sometimes it goes the opposite direction where a patient will say, "Oh, that is going to improve my survival by 5% and you can't give it to me now? I am going to choose to terminate." Even though that is obviously a very, very difficult and challenging decision to make in this setting because they want to optimize their survival and ideally live on to potentially have another pregnancy in the future if that is something that is of interest to her. So these are really, really hard conversations as you can imagine, but that is kind of where we go. Dr. Alison Loren: Yeah, and I think this is where the need for more research and understanding is really key because sometimes questions come up. I guess I am thinking about like HER2-directed agents, which we know are contraindicated in pregnancy. But what about sequencing? Does it matter when you get it? Can you get it later? I think that is something that we don't really fully understand. And similarly, again, this is obviously like a breast cancer and blood cancer focused discussion because that is what we do, but thinking about managing blood cancers, certainly with acute lymphoblastic leukemia, there is actually a lot of options now that, you know, you could potentially use to temporize or sort of get somebody through a pregnancy relatively safely. I am focusing on the word "relatively" because we do not know what the long-term impact might be of potentially not optimal therapy in the long run. And then thinking about other things like timing of a bone marrow transplant relative to either delivery or termination. I mean, again, we really do not know what are the right sets of sort of timing considerations for those. So there are just a lot of unknowns. And I think trying to be sort of self-aware and humble and honest about those unknowns so that the patient can engage in the conversation in a way that is meaningful to her and make the decisions that make the most sense for her. I think the most important thing is to make sure that the patient feels supported and safe to make those decisions with as little regret as possible. Brittany Harvey: Yes, I think it is really important that you mentioned that there is a wide range of cancers here, and that means that care really needs to be individualized for each patient. I will also note, just in this section, that I found really informative while reading through the guideline the list of oncologic agents that may be offered in each individual trimester, whether it is contraindicated or it can be used with caution, or if there is relatively good safety data on it for prioritizing maternal treatment needs and balancing fetal safety at the same time. I think that is, that is really key. And I think readers will really like that section of the guideline to provide concrete information for them and their patients. Dr. Alison Loren: Thank you. We actually spent a lot of time on that table and just thinking about what it should look like, what the format ought to be, what the language ought to be. Because of course, at the end of the day, everything should be used with caution. So what does that actually mean? And we sort of tried to explicate that a little bit in like the footnotes. We really tried to leverage what we know from clinical experience, from package labels, from mechanism of action to try to be as clear and definitive as we could be without overstating or understating what we know. Dr. Ann Partridge: Yeah, and I think we are focusing on breast and leukemia because that is what we do. But the truth is much of the data comes from those two areas. Leukemia, not because it is so common, but because you do not really have choices to treat or not treat. And so for decades, they have been treating and saying, "We hope the progeny comes out okay." And for many agents it does. The babies are okay. And so, we have reasonable observational data. And then in breast cancer, there have been actually some prospective registry-type studies where people have been followed and treated when pregnant, and the progeny have been accounted for, and so we have some good experience in that way too. Again, not randomized trials, but at least data that suggests certain agents are safe. And increasingly, because of that, when we have had to treat patients, we have said, "Okay, let us do it on this registry so that we can at least learn from every patient that comes in in this situation." And so, I think we will have more and more data given the growing number of young adults with cancer and the delays in childbearing that are happening around the world, and particularly in Westernized countries. I wish we did not. We wish we did not see this problem, but of course, when we do, we have to make sure that we learn from it and try and get patients enrolled in these registries and any kinds of studies that are available. Dr. Alison Loren: Yeah, I will just underscore that to say that, you know, there is outcomes of pregnancy and then there is outcomes of pregnancy, right? So there is like, "Okay, the baby was born with 10 fingers and 10 toes, and they passed their Apgar, and they are doing all their developmental processes along the way." But what happens when they are 10 or 15 or 20? Are they maturing normally? Are they cognitively intact? And then, of course, it is really inseparable from what is the impact on a family of having the mom with cancer? And how does that impact childhood development and intellectual development? And so these are really, really important questions that are very difficult to answer given the longitudinal information that you need, but it is a really critical question that, you know, patients ask and we do not know the answer. Dr. Ann Partridge: Yeah, that actually leads me to one of the important principles in the guideline that is a little bit of a change from when I first started practicing, which is we have learned from the wider neonatology literature, as they have followed up on the children that were born prematurely, that it is actually better not to be premature and to keep the baby in utero as long as it is safe for the fetus and the mother as long as possible, ideally to term rather than delivering early and then giving the chemo after that or separating the chemo from before and after. We used to try and deliver early and then give agents, but now we typically will give agents that are safe to be given at the end of pregnancy, ideally close to term, a couple weeks out, to allow for the ability of count recovery, and you do not want to go into preterm labor with chemotherapy on board, but we used to go much earlier and have an argument with our maternal-fetal medicine doctors. "How early can you get them out?" And they would say, "How long can they stay in?" And increasingly, we have been able to try and compromise to go even later and allow the fetus to go to term because of the neonatal outcomes that in longer term there is a suggestion that the children are developing better in the long run if they are kept in utero for as long as possible. Dr. Alison Loren: Yeah, that is such a great point. I think that is probably the most important thing for people to take away. For anyone who sort of does this, I mean, no one does this regularly because it is a rare event, although I think it is increasing as I mentioned. But this idea that the third trimester is, most of us know, is primarily a time for growth. Most of the critical development has already occurred, and so administering most chemotherapy agents towards the end of the third trimester seems to be preferable long term than delivering them early. So that is a really big change. I think we used to try to sort of, "Oh, get them to 30 or 32 weeks and then deliver," but we really are trying to get them closer to term, 37 weeks or more, and then coordinating the treatment so that they are not nadiring, as Ann said, at the time of planned delivery. Brittany Harvey: Yes, and that is a really important point related to evidence-based care and why we have changed that practice. And so then that actually leads nicely into my next question. But as you both mentioned, this is an important collaboration between oncologists and obstetricians. So the next section of the guideline addresses obstetrical practice. And so beyond what is standard, what additional recommendations are there in obstetrical management for pregnant patients with cancer? Dr. Alison Loren: That is a great question. So I will say we were really struggling with like how much do we cover? Like this is an oncology guideline. We are not obstetricians. We certainly had great representation from our maternal-fetal medicine colleagues on the panel. But really trying to sort of give useful information without overstepping. And so I think that the main recommendations are to increase the frequency of fetal monitoring, make sure that there is close attention to blood counts in the patient. But I think there is really still a gap in terms of what we know about optimal management of a pregnant person who is receiving therapy and how to handle the pregnancy itself. The delivery should be a usual delivery. Our colleagues did not recommend a planned C-section. They recommended usual care in terms of planning for the delivery. Obviously, if a C-section is indicated, then it should be done, but it should not be planned this way because of the cancer diagnosis. And I guess the other thing that we mentioned in the guideline, although we were reluctant to push it too hard because of access to these specialized services, was evaluating the placenta after birth to ensure that there were no metastases in the placenta itself. Dr. Ann Partridge: Those are the main things, and judicious and prudent obstetrical care, as I think, you know, is trying to be practiced regularly with MFM. Typically these patients should be followed not by your average OB/GYN, but a maternal-fetal medicine specialist because these patients will have special concerns, especially if they are sick. So oftentimes, especially Alison's patients, are actually sick with leukemia. And so you are monitoring them a lot, whereas, you know, a breast cancer patient typically isn't sick, although they could get sick with their chemotherapy. And so we really want to hand-in-hand manage these patients with our MFM colleagues. Dr. Alison Loren: I think we also highlighted in the guideline just for the refresher purposes of the oncology community, generally which drugs that would be given in a normal oncology setting are safe to be given to a pregnant person. So we talked a little bit about what kinds of steroids are recommended, antiemetics, DVT prophylaxis, peripartum. These are things that we think about a lot in oncology, but just want to make sure that it sort of intersected appropriately with the care of a pregnant patient. Brittany Harvey: Definitely. That specialized care is really important for patients who are pregnant and have cancer. And then the last section of the recommendations addresses psychological and social support. As you both mentioned before, this is a highly emotional time and it can be difficult and challenging to make decisions. So what is recommended for the psychological and social support of pregnant patients with cancer? Dr. Ann Partridge: Well, as I said, it is really something that needs to be considered at the beginning, through the diagnostic period, all the way into survivorship. Ironically, even though it is a highly fraught, emotional situation, I find that my pregnant patients actually are extraordinarily resilient, and what they are really focused on often is the safety of the fetus, because again, many of the people that come to me, it is a highly wanted pregnancy. They are also focused on their own health, of course, and often you need to bring in social work, sometimes a psychologist, professionals who are there just to help manage their emotions while we are focusing on what do they need medically to be as healthy as possible, both for the again, the mother, the patient, and the fetus. It is very tricky, and I will say also bringing in sometimes people on the ethics team in the hospital to help, both from the "Are you recommending and giving something that is safe?" That is number one. And then number two, sometimes patients want to be treated with drugs that we do not have any safety data for in pregnancy. What are our obligations? I think most of us would say we would not treat someone if we do not have safety data and there is suspicion for concern. But where is that line in terms of the right thing to do by that patient? And so we are all beholden to our ethics colleagues to help us when we make decisions like that. You know, we all want to do right by the patient, but we have to uphold our oaths and legal obligations. I don't know if you have to add on that because it's very tricky. Dr. Alison Loren: It is, it is very hard. I mean, I think, you know, there is a lot of emotion, obviously any cancer diagnosis is extremely charged and people are already at sort of a heightened, you know, they are anticipating a new baby and planning around that. And so it is just an extremely disruptive is the smallest word I can think of to describe it. And I think that often there is a co-parent, there might be parents and in-laws and other siblings, and then there is care after delivery. And so it is just a very complex set of dynamics. And having both our ethics colleagues and our psychology and social work colleagues to sort of just pitch in and make sure that the patient is being supported. I think there are sometimes really difficult situations where maybe what the patient wants is different from what the father of the baby wants or what the rest of the family wants. And so that can be really challenging. And you never really know where those landmines are going to pop up. So it is good to have the team on board early and often. Dr. Ann Partridge: Yeah, I would add to that, the other thing here that I think is really important, like in all of medicine but especially in situations like this, this is where we have to be very careful as professionals not to impose our own ethical, moral, emotional, personal views on the patient and to try to reserve judgment as much as possible. We are their navigator with the most important evidence and information that we can provide in the current situation. And that is where this guideline is extraordinarily helpful, we hope, for clinicians in the years to come. And at the same time, we cannot necessarily impose our own views and what we would do on a patient or what we tell our daughters, sisters, friends, family members. It is very tricky in that way. And so sometimes not just support for the patient, but support for the care team may be warranted in some of these very fraught situations. Dr. Alison Loren: Yeah, that is such a great point. And I was sort of thinking that too. I mean, it is, of course, the patient is front and center, but these are really difficult situations to navigate. And I will just add also that a lot of times these patients end up in academic centers, which I think is that's where the expertise or even just the experience may be. But the downside of that is that, you know, the teams are constantly changing. You have a new resident, you have a new intern, you have a new attending, a new fellow. And so, you know, the patients may be subjected to lots of different ways of communicating and sometimes those perceived differences can be really challenging. So sort of team huddles to sort of make sure that everybody is reading from the same script and everyone is comfortable with how the information is being presented so that the patient does not feel more confused or more overwhelmed, that they are kind of getting a consistent message from the whole team that, "This is what we know, this is what we are recommending, here are your other choices, and here are the pros and cons of each of these options." Brittany Harvey: Yes, I think you have both touched on this and that bringing in appropriate experts to support both clinicians and patients and their decision-making and their mental health is really important for this section of the guideline. We have already discussed this a fair bit throughout our conversation, but in your view, what is the importance of this guideline and how will it impact both clinicians and pregnant patients diagnosed with cancer? Dr. Ann Partridge: I could start with that. We just talked about experts and having them all around, but the fact is most people do not have the experts all around when they are dealing with this. And I think this is, you know, an expert-based, evidence-based guideline where having this in one's back pocket, whether you are in rural Montana or at a major cancer center on either coast, you will be armed with the latest and the greatest in terms of what we know and what we do not know, and some very helpful algorithms for how to think through the process of dealing with a patient who is diagnosed during pregnancy, whichever type of cancer it is. We could not cover every single specific thing about every cancer, although it is a pretty long guideline and there is a lot of nuance in there. So you might find a lot about specific cancers. And I think that that will be very, very helpful for people who are faced with this situation in the clinics just to frame it out, think through. Sometimes there is no answer that is the perfect answer and then, you know, using this as kind of a scaffolding and phoning a friend who may have more experience to help guide you and guide the patient, most importantly. I think it will be very helpful in that regard. Dr. Alison Loren: Yeah, I think so too. And I have talked about that we are working on this guideline and the anecdotal feedback has been, "This is so helpful." Like there really has not been, I think, an all-in-one place, diagnostic considerations, radiographic considerations, staging, treatment, all the modalities, surgical, radiation, systemic chemotherapy. We tried to include, when we could, novel agents including targeted agents and monoclonal antibodies and bispecifics and cellular immunotherapies and non-cellular immunotherapies. We really, really tried to cover in 2025 what are people using to treat cancer and to try to give the most balanced view of what we think is is safe or reasonably safe and what we think is either unproven or known to be risky, really to have it be kind of a go-to, like all-in-one, as much information as we have about these really challenging cases. We tried to include, Ann mentioned, you know, specific cancers, and I think when there were specific things to shout out with specific cancers, we really tried to highlight that. Like, "Okay, lots of young patients with cancer have Hodgkin's lymphoma, so what is safe and what is not for that specific case?" Or, "What is safe or what is not when you are thinking about colon cancers?" And we have a shout-out in here about considering checking for DPD deficiencies in patients who are pregnant. And I know it is generally recommended nowadays, but certainly for people who are pregnant, you know, you really want to avoid excess toxicity. So I think just really trying to be attentive to specifics about certain cancers in young patients and what would be valuable for a practicing oncologist and obstetrician to know when you are faced with this situation. Dr. Ann Partridge: Yeah, and I think the other critical thing that is great about this guideline is it's a starting place. And I anticipate that we will be building on this guideline for many years to come. And remember that when first, I was not around then, but probably three or four decades ago, when chemotherapy was just coming out and patients were coming in pregnant, there was a feeling I am sure that was, "We cannot give this to this person because it is purposefully going to destroy cells. And when you destroy cells in a growing fetus, you are going to destroy or harm that fetus." And yet, people did not have great choices. It was get treated or die, especially with things like leukemia early on. And bold patients along with their oncologist said, "Bring it on." And that is how some of this literature has been born. And so moving forward, there will be either purposeful exposures or inadvertent exposures of some of our therapies where we will learn ultimately. And this is a place where we can update these guidelines. That is the beautiful thing about the ASCO guidelines is that they are constantly being thought about to be updated. And then when there is enough of a change in practice, they will be updated such that they will continue to inform how we do this in the years to come for patients who come in pregnant. Dr. Allison Loren: Yeah, and I will say I have been doing this long enough now, we were just talking about a different guideline, the fertility guideline earlier today, and over the 20 years that the fertility guidelines have been out, just the amount of research has really skyrocketed. And you can see as you look at each guideline how much we have learned, what we can say, "Yes, this is working," "No, this is not working." Like, it is stuff that we used to say, "Oh, we do not really know," and now we have answers.  I think I speak for both of us when I say that we are hopeful that this will serve as, as Ann said, as a starting off point and really inspire people to ask the questions and do the research so that we can give better guidance moving forward, really trying to think about, you know, mechanisms and leaning on our colleagues in pharma and in the government who sort of think about safety and efficacy, to sort of make sure that they are contemplating not just non-pregnant patients, but also pregnant patients or as they are thinking about marking the package inserts with safety guidelines around this. Brittany Harvey: Yes, this is a critically important first guideline on the management of cancer during pregnancy, and we will look forward to continuing to build on that. I think as you mentioned, this guideline is far-reaching and has a lot of recommendations in it. And so both the full text of the guideline and those at-a-glance algorithms, figures, and tables will be really useful for clinicians in their clinic. Finally, to wrap us up, we have just been discussing this a little bit, but specifically, what are the outstanding questions on the management of pregnant patients with cancer, and where is this further research needed? Dr. Alison Loren: There are lots and lots and lots of unanswered questions. And I think if you look at the table, most of what we say is, "We are pretty sure this is okay, we are not so sure about this." I am paraphrasing, but we really just are operating in a paucity of what we would normally consider gold-standard evidence. It is hard to imagine, of course, there would ever be, as we mentioned in the beginning, randomized trials. But I think that preclinical data, mechanistic data, trying to think about including as we go through animal data, making sure that we are looking at female animals and pregnant animals so that we can sort of fully understand what the impact may be. And then I think thinking about more localized therapies around sort of radiation, you know, we are now moving into really hyper-focused radiation treatments like protons. Is that better because there is less scatter? Like I think those are real considerations that we just do not know the answer to. What do you think? Dr. Ann Partridge: I think so many unanswered questions, and this is a call to action to continue to and increase the documentation of the experiences and outcomes for patients diagnosed during pregnancy. Dr. Alison Loren: Yeah, and I think the long-term outcomes too are really going to be critical. Brittany Harvey: Yes, we will look forward to learning about more evidence across the spectrum of care to inform future updates to this guideline. So I want to thank you both so much for your work to develop this guideline, to review the extensive amounts of literature that you did, and work to create this guideline. And thank you also for your time today, Dr. Loren and Dr. Partridge. Dr. Alison Loren: Thanks. It was fun. Dr. Ann Partridge: Yeah, thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning into the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/survivorship-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 

Join Andy Cumpstey and Kate Leslie in this broadcast from the ANESTHESIOLOGY® 2025 meeting. They welcome guests Stacie G. Deiner, an anesthesiologist, professor and vice-chair for research at Dartmouth Hitchcock Medical Center and Mark D. Neuman, anesthesiologist and Horatio C. Wood Professor of Anesthesiology at the Perelman School of Medicine at the University of Pennsylvania. We discuss the new ASA guidelines for older adults. The episode delves into the development, significant recommendations, and implementation of these guidelines, emphasizing the importance of preoperative evaluation and the choice of anesthesia technique. Mark and Stacie also highlight ongoing research and the future of perioperative care for older adults. This conversation underscores the role of shared decision-making and proactive health measures in improving surgical outcomes. The ASA guideline can be found here: https://www.asahq.org/standards-and-practice-parameters/practice-advisory-perioperative-care-of-older-adults-scheduled-for-inpatient-surgery The REGAIN study can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2113514

About this episode: Since 2015, the American Academy of Pediatrics has recommended that parents and caregivers introduce peanuts to children's diets at around four to six months old to avoid the onset of a peanut allergy. In this episode: Pediatric allergist David Hill explains why early allergen introduction is safe and effective and how these recommendations have led to a significant reduction in peanut allergies in children. Guests: Dr. David Hill, PhD, is an allergist, immunologist, and an attending physician at the Children's Hospital of Philadelphia. He is also an assistant professor of pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Host: Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs. Show links and related content: Guidelines for Early Food Introduction and Patterns of Food Allergy—Pediatrics Peanut Allergies Have Plummeted in Children, Study Shows—New York Times Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy—New England Journal of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

This bonus episode is the audio of a Breastcancer.org ⁠webinar. For many people, life after breast cancer isn't as easy as just moving on. Physical side effects may linger, and the emotional healing is ongoing. Fear of recurrence can affect our mental health and relationships even when we are doing our best to live in the moment. Listen to this webinar for an honest conversation between breast cancer survivors about realistically managing anxiety and stress, staying active, and finding a balanced healthy lifestyle. You'll also hear from medical experts about survivorship care plans, and their perspective on making healthy choices without putting too much pressure on yourself to be perfect.  Special thanks to ArmorUp for Life for partnering with Breastcancer.org on the webinar. Read more about getting the best follow up care for you. Featured Speakers: Marisa Weiss, MDChief Medical Officer, Breastcancer.org Kevin Fox, MDEmeritus Professor of Medicine, Perelman School of Medicine at University of Pennsylvania Loriana Hernández-AldamaFounder, ArmorUp for LIFE Charlene AbramsBreast Cancer Survivor and Advocate Carolyn TeschlerBreast Cancer Survivor and Advocate Epiphany Wallner-HaasBreast Cancer Survivor and Advocate

Send us a textDr. Matt Bernstein is a returning guest on our show! Be sure to check out her first appearance on episode 747 of Boundless Body Radio!Dr. Matthew Bernstein is Accord's chief executive officer and one of the leading voices in the emerging field of metabolic psychiatry. He is a well-respected clinical psychiatrist for more than 25 years.After graduating summa cum laude from Columbia University in New York, N.Y., with a bachelor's degree in English literature, he received his medical degree from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, PA. Dr. Bernstein then trained at the MGH McLean Psychiatry Residency Program in Belmont, Mass., where he served as chief resident. He remained at McLean Hospital after residency as a psychiatrist-in-charge and later served as assistant medical director of its schizophrenia and bipolar inpatient program.Dr. Bernstein has developed his passion for community-based care as the chief medical officer at Ellenhorn, a sister program of Accord, where he has pursued alternative ways (such as a focus on metabolism, nutrition, circadian-rhythm biology and exercise) to help individuals achieve their best levels of functioning without relying solely on traditional psychiatric approaches.Central to Accord's mission is the enhancement of metabolic health, recognizing its profound impact on mental well-being. Their focus lies in crafting personalized plans centered around enhancing metabolic health through nutrition, exercise, mind-body practices and circadian rhythm alignment.With a full-time chef at their service, clients not only enjoy expertly prepared meals but also receive hands-on culinary education. Regular consultations with our nutritionist/dietitian ensure that each client's plan is finely tuned to their unique requirements.In addition to serving on the clinical advisory board at Metabolic Mind, Dr. Bernstein is known for organizing the first-ever public conference on metabolic psychiatry in 2023.Find Dr. Matthew Bernstein at-https://accordmh.com/TW- @AccordMetabolicLK- @Accord MHFind Boundless Body at- myboundlessbody.com Book a session with us here!

Dr. Frank Leone is a Professor of Medicine in the Perelman School of Medicine, University of Pennsylvania. He directs Penn's Comprehensive Smoking Treatment Program, offering multidisciplinary collaborative patient care to people suffering complex manifestations of tobacco use disorder. Dr. Leone is a Senior Fellow of the Leonard Davis Institute of Health Economics. His scholarship focuses on investigating advanced treatment strategies for tobacco use disorder and on testing strategies for improving the care of the tobacco dependent patient. Dr. Leone has published over 130 peer-reviewed papers and, along with Ms. Evers-Casey, has co-authored a clinical handbook of tobacco dependence treatment titled Why People Smoke: An Innovative Approach to Treating Tobacco Dependence. Today on the show we discuss: why vaping isn't actually safer than cigarettes, how vape aerosols damage your lungs and heart even without traditional carcinogens, the hidden addiction mechanics that make nicotine one of the hardest habits to break, why vaping increases anxiety, depression, and the risk of other substance addictions, how to finally quit vaping for good  proven strategies, how parents and loved ones can help without judgment or shame and much more. ⚠ WELLNESS DISCLAIMER ⚠ Please be advised; the topics related to health and mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your health or mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed. If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org.  SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

Interviewer: MATTHEW ROTH. Anti-vaccine rhetoric is on the rise in the U.S., encouraged now by MAHA-dominated health policies emerging from Washington. It is tempting to paint this as a top-down process, but neonatologist and immunologist BENJAMIN A. FENSTERHEIM argues that the problem runs deeper and is rooted in the institutional arrangements of our healthcare system. In his conversation with historian Matthew Roth, he describes his work caring for newborns, the increasing pushback by parents against routine preventive measures, and his reflections on how the relationship between doctors and patients must fundamentally change to ensure that the best medical decisions are made. Fensterheim is an Attending Neonatologist with the Division of Neonatology at the Children's Hospital of Philadelphia and an Instructor at the Perelman School of Medicine at the University of Pennsylvania.

Dr. David Fajgenbaum, MD, MBA, MSc, is a pioneering physician-scientist, tenured professor at the Perelman School of Medicine at the University of Pennsylvania, and national bestselling author who transformed his personal battle with the rare, deadly Castleman disease into a global mission to accelerate cures for humanity's 12,000 known diseases. Diagnosed after losing his mother to cancer, Fajgenbaum endured five near-death experiences before using his medical training to identify sirolimus—a repurposed drug—as a life-saving treatment, achieving remission marking over a decade cancer-free as of 2025. A Georgetown University graduate with advanced degrees from Oxford and Wharton, he co-founded the Castleman Disease Collaborative Network (CDCN) and Every Cure, leveraging AI and drug repurposing to unlock hidden treatments, earning spots on TIME's 2025 TIME100 Health list and major media recognition for his "cure thyself" story. Through his book Chasing My Cure and speaking engagements, Fajgenbaum inspires hope, advocates for patient-driven research, and pushes for policy changes to speed up cures for rare diseases affecting millions worldwide. Shawn Ryan Show Sponsors: https://americanfinancing.net/srs NMLS 182334, nmlsconsumeraccess.org. APR for rates in the 5s start at 6.327% for well qualified borrowers. Call 866-781-8900, for details about credit costs and terms. https://bunkr.life – USE CODE SRS Go to https://bunkr.life/SRS and use code “SRS” to get 25% off your family plan. https://shawnlikesgold.com https://ROKA.com – USE CODE SRS https://simplisafe.com/srs https://USCCA.com/srs https://ziprecruiter.com/srs https://gemini.com/srs Sign up for the Gemini Credit Card: https://Gemini.com/SRS #GeminiCreditCard #CryptoRewards #Advertisement This video is sponsored by Gemini. All opinions expressed by the content creator are their own and not influenced or endorsed by Gemini. The Bitcoin Credit Card™ is a trademark of Gemini used in connection with the Gemini Credit Card®, which is issued by WebBank. For more information regarding fees, interest, and other cost information, see Rates & Fees: gemini.com/legal/cardholder-agreement. Some exclusions apply to instant rewards; these are deposited when the transaction posts. 4% back is available on up to $300 in spend per month for a year (then 1% on all other Gas, EV charging, and transit purchases that month). Spend cycle will refresh on the 1st of each calendar month. See Rewards Program Terms for details: gemini.com/legal/credit-card-rewards-agreement. Checking if you're eligible will not impact your credit score. If you're eligible and choose to proceed, a hard credit inquiry will be conducted that can impact your credit score. Eligibility does not guarantee approval. The appreciation of cardholder rewards reflects a subset of Gemini Cardholders from 10/08/2021 to 04/06/2025 who held Bitcoin rewards for at least one year. Individual results will vary based on spending, selected crypto, and market performance. Cryptocurrency is highly volatile and may result in gains or losses. This information is for general informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Consult with your tax or financial professional before investing. Dr. David Fajgenbaum Links: Website - https://davidfajgenbaum.com X - https://x.com/DavidFajgenbaum IG - https://www.instagram.com/dfajgenbaum LI - https://www.linkedin.com/in/davidfajgenbaum Every Cure - https://everycure.org Castleman Disease Collaborative Network - https://cdcn.org TED talk - go.ted.com/davidfajgenbaum TED YT - https://youtu.be/sb34MfJjurc Chasing My Cure (Amazon) - https://www.amazon.com/Chasing-My-Cure-Doctors-Action/dp/1524799637 Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adam Siebert, Managing Director and Partner at L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering: Adam's journey from academic to commercial, and what helped him transition into 'life science enablers". How pandemic demand has left our sector with a huge over capacity issue and market imbalance. Some positive signals for the second half of 2025 after a period of geopolitical chaos, and a bumpy rollercoaster. Even thought biotech funding has largely returned... how decreasing clinical trials, a shifting of therapeutic focus, and the concentration of investments on fewer, higher value deals is impacting pharma services. The value of building a reputation in one in-demand modality area before extending into other modalities. And why the CDMO is at an inflexion point... Adam is a Managing Director and Partner in L.E.K. Consulting's New York office and a member of the Life Sciences practice. He has been with L.E.K. for over eight years, and has experience across diagnostics and research tools, bioprocessing and pharma services, and emerging, mid-cap and large pharma. Adam has helped a number of clients in the life sciences industry with growth strategy, life cycle management, portfolio optimization and M&A projects. Adam holds a Bachelor of Science from Boston College and a Ph.D. from the Perelman School of Medicine at the University of Pennsylvania.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored by Bora Pharma (boracdmo.com) and Charles River (www.criver.com), and supported by ramarketing.

Pediatric rheumatologist Dr. Pamela Weiss speaks with Michael and his 12 year old daughter Ava about  navigating the challenge of living with psoriasis and psoriatic arthritis together as a family.   Join moderator Kaleigh Welch as she discusses the challenges of living with psoriasis and juvenile psoriatic arthritis (JPsA) from diagnosis, misconceptions about psoriatic disease, to management and treatment with pediatric rheumatologist, Dr. Pamela Weiss from Children's Hospital of Philadelphia, Division of Rheumatology, along with Michael and Ava, whose psoriatic disease is truly a family affair. The intent of this episode is to raise awareness about the complexities and nuances associated with living with psoriasis and psoriatic arthritis as a child or an adult and not letting the disease stop you from doing what you love to do. This episode is sponsored by Amgen. Mike, Ava, and Dr. Weiss were compensated for their time. Timestamps: ·       (0:00) Intro to Psoriasis Uncovered and guest welcome pediatric rheumatologist Dr. Pamela Weiss, Michael and Ava Sayles who both have been diagnosed with psoriasis and psoriatic        arthritis.   ·       (1:28) What the psoriatic disease diagnosis process could be like for children and adults.   ·       (5:34) Misconceptions associated with psoriasis leading to delayed diagnosis of psoriatic arthritis. ·       (7:36) What people misunderstand about plaque psoriasis and psoriatic arthritis. ·       (11:06) Challenges to finding the right treatment while living life with psoriatic disease. ·       (17:24) What drives treatment choices for psoriatic disease in youth. ·       (19:59) Assessing what's most important in reaching treatment goals. ·       (23:57) What the future holds for management of Juvenile Psoriatic Arthritis (JPsA). ·       (26:10) Living with psoriatic disease is challenging but find what's right for you and don't give up on what you love to do. Key Takeaways: ·       Diagnosis of plaque psoriasis and psoriatic arthritis can be challenging given subtleties that can occur in the presentation of the disease in adults and children. ·       There are a variety of treatments that work either alone or in combination to treat plaque psoriasis and psoriatic arthritis with choice of treatment dependent on what is the primary goal for the individual's physical and emotional health. ·       The future is bright as understanding of the disease increases and treatment options expand and become more targeted to more effectively address skin and joint issues associated with psoriatic disease. Guest Bios:   Pamela Weiss, M.D., MSCE, is a pediatric rheumatologist and the Clinical Research Director of the Division of Rheumatology at Children's Hospital of Philadelphia. Dr. Weiss is also the Distinguished Endowed Chair in the Department of Pediatrics. She has advanced training in clinical epidemiology with a focus on early diagnosis, and targeted treatment of children with spondyloarthritis (SpA). Dr. Weiss is also a Professor of Pediatrics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. She is a member of the American Academy of Pediatrics, American College of Rheumatology, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the Spondylitis Association of America, and the SPondyloArthritis Research & Treatment Network (SPARTAN). Michael and Ava Sayles, psoriatic disease is a family affair. Both father and daughter, successfully navigate living with plaque psoriasis and psoriatic arthritis. Michael or Mike was diagnosed in his twenties, and Ava at age 7 and then later on juvenile psoriatic arthritis. She is now 12 years old.  They have experienced issues with diagnosis, and a long journey of finding treatment options that worked for them. Mike found the best solution was establishing a routine or rhythm of treatment around work and school to avoid flare-up's if possible, saying “keeping on top of what you need to do for the psoriasis and the arthritis becomes a big part of your life".  Resources: Our Spot: What is Psoriatic Arthritis  

The role of neuronal influences on cancer pathogenesis and progression is increasingly appreciated in the nervous system. Neurons have been shown to enhance the proliferation and migration of gliomas, a glial-derived tumor of the CNS, via diffusible paracrine factors or synaptic inputs onto tumor cells. In glioblastomas, a highly aggressive glioma, mostly glutamatergic inputs have been identified. While the potential for glioblastomas to receive projections from neurons of other neurotransmitter subtypes, such as from cholinergic neurons, has recently been discovered in xenotransplantation models, whether synapses can form between human cholinergic neurons and glioblastoma cells and consequences of these inputs and other non-synaptic mechanisms are still unknown.   Human induced pluripotent stem cell-based models have been emerging as a powerful platform for studying human-specific disease mechanisms. Today's guests developed a co-culture model for the study of neuron-tumor interactions by combining patient derived glioblastoma organoids and hiPSC-derived cholinergic neurons. They will discuss their recent findings and what it means for understanding and potentially treating a tumor for which there is no known cure. GuestsGuo-li Ming, MD, PhD, Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine, University of PennsylvaniaHongjun Song, PhD, Department of Neuroscience and Mahoney Institute for Neurosciences, Perelman School of Medicine, University of Pennsylvania Yusha Sun, Neuroscience Graduate Group, Perelman School of Medicine, University of PennsylvaniaHostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting ContentPaper link:  Cholinergic neuron-to-glioblastoma synapses in a human iPSC-derived co-culture model, Stem Cell ReportsAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Senior Marketing ManagerJack Mosher, Scientific DirectorHunter Reed, Senior Marketing Coordinator

In this informative episode, Dr. Reid Mergler, Assistant Professor of Clinical Psychiatry at University of Pennsylvania and Reproductive Psychiatrist at Penn Center for Women's Behavioral Wellness, describes how you can recognize this common diagnosis, Polycystic Ovary Syndrome (PCOS), and how to get the support you need.

On June 18, Tradeoffs moderated an online event with economists and doctors examining why this legislation could cost so many people their health coverage — or even their lives.Guests:Eric Roberts, Associate Professor, Department of General Internal Medicine, Perelman School of MedicineAditi Vasan, Assistant Professor, Department of Pediatrics, Perelman School of MedicineRachel Werner, Executive Director, Leonard Davis Institute of Health Economics, University of PennsylvaniaLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

Today on One Life Radio, Bernadette is joined by Andrew Colsky, “The Sleep Science Guy,” They covered some of the latest trends in getting a good night's rest.Andrew Colsky, JD, LPC, LMHC, (Juris Doctor, Licensed Professional Counselor, Licensed Mental Health Counselor) is a nationally recognized behavioral sleep expert with over 15 years of clinical experience.He specializes in Cognitive Behavioral Therapy for Insomnia (CBT-I) and nightmares (CBT-N), holds a mini-fellowship in sleep science from The University od Pennsylvania's Perelman School of Medcine, and is the founder of the National Sleep Center.As the creator and host of “Sleep Science Today,” Andrew merges education, advocacy, and media to bring the science of sleep to the public in an accessible, engaging way.Andrew is trusted by healthcare leaders and loved by everyday listeners for his ability to cut through the noise and deliver actionable advice - backed by real science.Learn more about Andrew at sleepscienceguy.comInstagram: @sleepscienceguy & @sleepsciencetoday

Grant funding by the National Science Foundation has been cut by more than half this year, bringing the foundation's science funding to its lowest level in decades. Katrina Miller, who covers science for the New York Times, joins Host Flora Lichtman to unpack the cutbacks and discuss where the funding changes might lead.And, the FDA has cleared a blood test to help diagnose Alzheimer's disease. The first-of-its-kind test measures the levels of amyloid and tau proteins in a patient's blood, two major biomarkers of the disease. Alzheimer's researcher Jason Karlawish joins Flora to explain this new diagnostic tool and what it means for patients.Guests:Katrina Miller is a science reporter for The New York Times based in Chicago.Dr. Jason Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania's Perelman School of Medicine, and co-director of the Penn Memory Center, based in Philadelphia, Pennsylvania.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

The Rich Zeoli Show- Hour 4: 6:05pm- On Thursday, the Trump Administration threatened to withhold federal funding from several sanctuary cities—including Philadelphia, New York City, Los Angeles, and Chicago—if they don't comply with federal law enforcement authorities seeking to crackdown on illegal immigration and the deportation of dangerous migrants residing in the country unlawfully. 6:15pm- While appearing on CNN, White House Deputy Chief of Staff Stephen Miller absolutely destroyed host Pamela Brown when she attempted to downplay border security and the deportation of potentially dangerous migrants who entered the U.S. unlawfully. 6:30pm- Friday marked Elon Musk's last day leading the Department of Government Efficiency (DOGE). President Donald Trump praised Musk's work, highlighting several instances of federal waste that were discovered under his leadership: $101 million for DEI contracts at the Department of Education, $59 million for illegal alien hotel rooms in New York City, $45 million for DEI scholarships in Burma, $42 million for social and behavioral change in Uganda, $20 million for Arab Sesame Street, and $8 million for making mice transgender. As a thank you, Trump presented Musk with a golden key to the White House. 6:40pm- Dr. Stanley Goldfarb—Chairman of Do No Harm & a Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania—joins The Rich Zeoli Show to discuss Penn Medicine's decision to stop performing sex-change surgeries on children. They will, however, continue to prescribe irreversible puberty blockers for children.

Click here to send us a topic idea or question for Weekend Wisdom.Do you want to raise kids who you will like and want to hang out with as adults? Listen to this interview with Dr. Ginsburg, a pediatrician at Children's Hospital of Philadelphia and professor of pediatrics at U Penn's Perelman School of Medicine. He is the author of Lighthouse Parenting: Raising Your Child With Loving Guidance for a Lifelong Bond, and the founder of the Center for Parent and Teen Communication.In this episode, we discuss:Definition of Lighthouse Parenting (7 key elements):StabilityModeling & KnowingCommunicatingProtectingResilience & ThrivingPreparationReliabilityBenefits of Lighthouse/Balanced ParentingMisunderstanding of attachment/trauma-sensitive parenting as permissive parenting.Self-care as the foundation of Lighthouse Parenting, “Stability: Finding Your Footing.” Why start there? Why is self-care critical to being a balanced parent?6 key elements of self-care and examples of how each might look for parents and caregivers who feel they cannot prioritize self-care:Love and friendshipsSleepExercise/MovementRelaxation strategiesExpress emotionsRecognize and reach for supportOffer 1 or 2 practical tips for parenting with this lifelong bond in mind for parents with: Elementary-aged kidsTweens and teensYoung adults (college or early career age)Support the showPlease leave us a rating or review. This podcast is produced by www.CreatingaFamily.org. We are a national non-profit with the mission to strengthen and inspire adoptive, foster & kinship parents and the professionals who support them.Creating a Family brings you the following trauma-informed, expert-based content: Weekly podcasts Weekly articles/blog posts Resource pages on all aspects of family building

The #1 killer in the world is heart disease—it doesn't matter who you are or where you live, this killer doesn't discriminate. But does it have a code? And could it be cracked with the right technology? Tune in to discover: Why all of our cells would burst without cholesterol, but what happens when there's too much of it How CRISPR/Cas9 technology could hold the key to permanently low cholesterol levels (without the need for injections or pills), and a cure for sickle cell anemia What lipid nanoparticles are, how they can be used to deliver genes to specific organs in the body, and why this is significant Dr. Kiran Musunuru is a cardiologist, professor of medicine, and director of the Genetic and Epigenetic Origins of Disease Program at Perelman School of Medicine, University of Pennsylvania. As the leading cause of death globally, he believes heart disease is the preeminent global health threat of the 21st century, and the greatest challenge facing the medical profession today. And this is driving him to take action. Dr. Musunuru explains that, despite immense efforts put forth by some of the brightest scientists and doctors over the course of decades, treatment options for heart disease remain limited, mostly to cholesterol-lowering drugs. But he also explains how this is changing in light of the more recent revolution in genetics—namely, the completion of the Human Genome Project. What's the genetic difference between those who develop heart disease and those who don't? What genes influence heart health and disease, and could therapies based on this information prevent heart disease altogether? These are the types of questions that Dr. Musunuru says can now be answered, and he's doing just that. Listeners will learn about the genetics behind heart disease and cholesterol levels, the details of Dr. Musunuru's research and most recent findings, what the future of heart disease treatment and prevention might hold, and much more. Learn more at https://www.med.upenn.edu/cvi/musunuru-laboratory.html. Episode also available on Apple Podcasts: http://apple.co/30PvU9 Upgrade Your Wallet Game with Ekster!  Get the sleek, smart wallet you deserve—and save while you're at it! Use coupon code FINDINGGENIUS at checkout or shop now with this exclusive link: ekster.com?sca_ref=4822922.DtoeXHFUmQ5  Smarter, slimmer, better. Don't miss out!